Cresco Labs (CRLBF) Non-Current Assets (2019 - 2026)
Cresco Labs' (CRLBF) quarterly Non-Current Assets came in at $952.2 million in Q1 2026, down 9.57% YoY from $1.1 billion in Q1 2025, and up 1.51% on a QoQ basis from $938.0 million in Q4 2025.
Cresco Labs (CRLBF) Non-Current Assets (2019 - 2026) Analysis & Trends
Cresco Labs (CRLBF) has 8 years of Non-Current Assets data on file, last reported at $952.2 million in Q1 2026.
- Quarterly Non-Current Assets fell 9.57% year-over-year to $952.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $952.2 million (down 9.57% YoY) and the FY2025 annual result came in at $938.0 million, down 11.6% from the prior year.
- Non-Current Assets advanced to $952.2 million in Q1 2026, from $938.0 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.4 billion in Q3 2022 to a low of $938.0 million in Q4 2025.
- A 5-year average of $1.1 billion and a median of $1.1 billion in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 35.08% — and 2023, when it fell 21.78%.
- Tracing CRLBF's Non-Current Assets over 5 years: stood at $1.3 billion in 2022, then retreated by 14.1% to $1.1 billion in 2023, then decreased by 1.78% to $1.1 billion in 2024, then fell by 11.6% to $938.0 million in 2025, then climbed by 1.51% to $952.2 million in 2026.
- The last three Non-Current Assets figures came in at $952.2 million (Q1 2026), $938.0 million (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Cresco Labs | 295.09 Mn | 230.98 Mn | 86.95 Mn | 1.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 952.19 Mn |
| Dec 31, 2025 | 938.03 Mn |
| Sep 30, 2025 | 1.04 Bn |
| Jun 30, 2025 | 1.03 Bn |
| Mar 31, 2025 | 1.05 Bn |
| Dec 31, 2024 | 1.06 Bn |
| Sep 30, 2024 | 1.07 Bn |
| Jun 30, 2024 | 1.08 Bn |
| Mar 31, 2024 | 1.07 Bn |
| Dec 31, 2023 | 1.08 Bn |
| Sep 30, 2023 | 1.10 Bn |
| Jun 30, 2023 | 1.25 Bn |
| Mar 31, 2023 | 1.26 Bn |
| Dec 31, 2022 | 1.26 Bn |
| Sep 30, 2022 | 1.40 Bn |
| Jun 30, 2022 | 1.39 Bn |
| Mar 31, 2022 | 1.39 Bn |
| Dec 31, 2021 | 1.36 Bn |
| Sep 30, 2021 | 1.12 Bn |
| Mar 31, 2021 | 1.03 Bn |